drug · unknown

RYTELO

updated 3mo ago

by $GERN GERON CORP🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Unknown drug with a maximum clinical stage of Approval (across all indications), with an approval for anemia and 5 investigational indications.

targets

Telomerase reverse transcriptase

all catalysts(0)

nothing on the calendar yet

Trials studying RYTELO

phase1A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosisrecruitingn=36
phase3Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)active not recruitingn=289
phase2Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapyactive not recruitingn=46

News(0)

no news has mentioned this drug yet

brand

RYTELO

trade names

Rytelo

generic

IMETELSTAT SODIUM

MOA

12.1. Mechanism of Action Imetelstat is an oligonucleotide human telomerase inhibitor that binds to the template region of the RNA component of human telomerase (hTR), inhibits telomerase enzymatic activity and prevents telomere binding. Increased telomerase activity and human telomerase reverse transcriptase (hTERT) RNA expression have been reported in MDS and malignant stem and progenitor cells. Nonclinical studies showed imetelstat treatment led to reduction of telomere length, reduction of malignant stem and progenitor cell proliferation, and induction of apoptotic cell death.

indication

1. INDICATIONS AND USAGE RYTELO is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). RYTELO is an oligonucleotide telomerase inhibitor indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA). ( 1 )

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 25m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

drug · unknown

save

RYTELO

updated 3mo ago

by $GERN GERON CORP🔗 ChEMBL

community read0 votes

🐶 often sniffed alongside

top 2

Unknown drug with a maximum clinical stage of Approval (across all indications), with an approval for anemia and 5 investigational indications.

targets

Telomerase reverse transcriptase

all catalysts(0)

nothing on the calendar yet

Trials studying RYTELO

phase1A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosisrecruitingn=36
phase3Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)active not recruitingn=289
phase2Study to Evaluate Imetelstat in Patients With High-Risk MDS or AML Failing HMA-based Therapyactive not recruitingn=46

News(0)

no news has mentioned this drug yet

brand

RYTELO

trade names

Rytelo

generic

IMETELSTAT SODIUM

MOA

indication

Data sources

ClinicalTrials.gov · OpenTargets

last refreshed 25m ago

Found something off?

comments(0)

5-min edit window · permanent after that

no comments yet — first sniff?

RYTELO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying RYTELO

News(0)

Report a data issue

comments(0)

RYTELO

🐶 often sniffed alongside

targets

all catalysts(0)

Trials studying RYTELO

News(0)

Report a data issue

comments(0)